Related Experiment Video

Updated: Sep 12, 2026

Experimental Metastasis Assay
08:28

Experimental Metastasis Assay

Published on: August 25, 2010

Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer.

R S Kerbel1

  • 1Cancer Research Division, Sunnybrook Health Science Center, Toronto, Ontario, Canada.

The American Journal of Pathology
|September 1, 1992
PubMed

Insights

Malignant tumor progression involves acquiring resistance to multiple cytokines and growth factors. This allows cancer cells to metastasize and grow in new environments.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Biology

Background:

  • Malignant tumor progression is characterized by complex cellular adaptations.
  • Understanding the mechanisms of tumor growth and metastasis is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To review evidence on how tumor cells acquire resistance to growth inhibitory cytokines and growth factors.
  • To explore the concept of growth factor 'switching' during tumor progression and metastasis.

Main Methods:

  • Literature review focusing on human melanoma and related cancer biology studies.
  • Analysis of cellular phenotypes associated with malignant tumor progression.

Main Results:

  • Evidence suggests that tumor cells develop resistance to multiple, diverse growth inhibitory cytokines during progression.
  • Tumor cells also exhibit pleiotropy in acquiring independence from growth factors.
  • Growth factors can shift from inhibitory to mitogenic roles for advanced-stage tumor cells, facilitating metastasis.

Conclusions:

  • The combined phenotypes of multicytokine resistance and multi-growth factor independence are key for tumor cell survival and growth.
  • These adaptations enable tumor cells to invade the primary site mesenchyme and establish distant metastases.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...